108 related articles for article (PubMed ID: 21528183)
1. Bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder cancer.
Mizutani Y; Yoshida O; Bonavida B
Int J Oncol; 1997 Jul; 11(1):79-86. PubMed ID: 21528183
[TBL] [Abstract][Full Text] [Related]
2. Therapy of superficial bladder cancer.
Nseyo UO; Lamm DL
Semin Oncol; 1996 Oct; 23(5):598-604. PubMed ID: 8893870
[TBL] [Abstract][Full Text] [Related]
3. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
4. Superficial bladder cancer therapy.
Schenkman E; Lamm DL
ScientificWorldJournal; 2004 Jun; 4 Suppl 1():387-99. PubMed ID: 15349563
[TBL] [Abstract][Full Text] [Related]
5. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
6. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
7. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
8. Prevention of the Recurrence of Superficial Bladder Cancers: Intravesical Instillation of Bacillus Calmette-guerin Versus Bacillus Calmette-guerin Plus Epirubicin.
Tozawa K; Okamura T; Yamada Y; Hayashi Y; Sasaki S; Kohri K
Asian Pac J Cancer Prev; 2000; 1(3):217-220. PubMed ID: 12718668
[TBL] [Abstract][Full Text] [Related]
9. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group.
Kurth KH; Bouffioux C; Sylvester R; van der Meijden AP; Oosterlinck W; Brausi M
Eur Urol; 2000; 37 Suppl 3():1-9. PubMed ID: 10828681
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: the impact of previous intravesical treatment.
Okamura T; Akita H; Imura M; Kaneko T; Mizuno K; Tozawa K; Kohri K
Int J Urol; 2008 Oct; 15(11):976-80. PubMed ID: 18721199
[TBL] [Abstract][Full Text] [Related]
11. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
12. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
Gandhi NM; Morales A; Lamm DL
BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
[TBL] [Abstract][Full Text] [Related]
13. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
14. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
Demkow T; Alter A; Wiechno P
Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
[TBL] [Abstract][Full Text] [Related]
15. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
[TBL] [Abstract][Full Text] [Related]
16. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
[TBL] [Abstract][Full Text] [Related]
17. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
19. Bladder contracture: review for intravesical bacillus Calmette-Guerin complication.
Hameed A; Sezian N; Thwaini A
Can J Urol; 2007 Dec; 14(6):3745-9. PubMed ID: 18163926
[TBL] [Abstract][Full Text] [Related]
20. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial.
Herr HW; Schwalb DM; Zhang ZF; Sogani PC; Fair WR; Whitmore WF; Oettgen HF
J Clin Oncol; 1995 Jun; 13(6):1404-8. PubMed ID: 7751885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
